difference in endpoint psg measures of sleep for patients treated with pregabalin & placebo
Post on 03-Jan-2016
15 Views
Preview:
DESCRIPTION
TRANSCRIPT
Difference in Endpoint PSG Measures of Sleep (4 weeks)
PSG Measure StatisticPlacebo (n=109)
Pregabalin (n=108)
WASO, mina
LS mean ± SE 72.5±3.4 53.2±3.4
LS mean difference (95% CI) from placebo
-19.3 (-26 to -12.7)***
TST, minb
LS mean ± SE 370.6±4.7 396.2±4.7
LS mean difference (95% CI) from placebo
25.5 (17.5) to -33.6)***
LPS, minc
LS mean ± SE 41.6±3.7 34.5±3.7
LS mean difference (95% CI) from placebo
-7.2 (-14.2 to -0.17)**
Notes
*** P<0.0001; ** P=0.0447LS, least squares; SE, standard error; CI, confidence intervala Decrease in WASO was similar (-19.2 [-26.7 to -11.6]; P<0.0001) for primary endpoint WASO analyses performed on the per-protocol population.b Higher LS mean values (positive mean difference) indicate improved sleepc Higher LS mean values (negative mean difference) indicate improved sleep
Difference in Endpoint PSG Measures of Sleep for Patients Treated with Pregabalin & Placebo
top related